Application of Physiologically‐Based Pharmacokinetic Modeling to Predict Gastric pH‐Dependent Drug–Drug Interactions for Weak Base Drugs-Reference-Cited by-同舟云学术

Application of Physiologically‐Based Pharmacokinetic Modeling to Predict Gastric pH‐Dependent Drug–Drug Interactions for Weak Base Drugs

Published:2020-07-31 Issue:8 Volume:9 Page:456-465
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Dong Zhongqi¹,Li Jia¹,Wu Fang²,Zhao Ping¹,Lee Sue‐Chih¹,Zhang Lillian³,Seo Paul²,Zhang Lei¹

Affiliation:

1. Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA

2. Office of New Drug Products Office of Pharmaceutical Quality Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA

3. Office of Policy for Pharmaceutical Quality Office of Pharmaceutical Quality Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA

Publisher

Wiley

Subject

Pharmacology (medical),Modelling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12541

Reference43 articles.

1. Managing potential drug-drug interactions between gastric acid-reducing agents and antiretroviral therapy: experience from a large HIV-positive cohort

2. Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?

3. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals

4. Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use

5. pH-Dependent Drug–Drug Interactions for Weak Base Drugs: Potential Implications for New Drug Development

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategy to Improve the Oral Pharmacokinetics of Cyclin-Dependent Kinase 4/6 Inhibitors: Enhancing Permeability and CYP450 Inhibition by a Natural Bioenhancer;AAPS PharmSciTech;2024-08-08

2. Model‐informed Drug Development ( MIDD ) Regarding Regulatory Requirements and Thinking;Exploring Computational Pharmaceutics ‐ AI and Modeling in Pharma 4.0;2024-06-21

3. Assessing and mitigating pH-mediated DDI risks in drug development – formulation approaches and clinical considerations;Drug Metabolism Reviews;2024-05-03

4. Physiologically based absorption modeling to predict the bioequivalence of two apixaban formulations;Clinical and Translational Science;2024-05

5. A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug–drug interactions;CPT: Pharmacometrics & Systems Pharmacology;2024-05